Shots:
- Tempus AI has received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead ECGs for signs associated with pulmonary hypertension (PH)
- Designed for patients aged 40 and older with cardiovascular symptoms but no known PH history, Tempus ECG-PH identifies ECG patterns associated with elevated mean pulmonary artery pressure
- Tempus ECG-PH analyzes ECG data to provide a binary output and adds pulmonary hypertension to Tempus’ FDA-cleared AI tools for atrial fibrillation & low ejection fraction
Ref: Businesswire | Image: Tempus AI | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
